Unique Target Selection Strategy Drives Best-In-Class Pipeline



           Strong                S TAT 6        Large clinical/
           genetic/clinical                     commercial
           validation                           opportunities




           Undrugged or
           inadequately       IRF5              Clear path to
                                                early clinical
           drugged                   IRAK4      differentiation
           targets


                           FOCUS ON FIRST- AND
                       BEST-IN-CLASS OPPORTUNITIES
                                                                  8
